TUKYSA

(tucatinib)

Find TUKYSA medical information:

Find TUKYSA medical information:

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

TUKYSA Quick Finder

    The Summary of Product Characteristics (SPC) for Tukysa, film-coated tablets (50mg or 150mg) is available here. 

    TUKYSA (tucatinib) is indicated in combination with trastuzumab and capecitabine for the treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer who have received at least 2 prior anti-HER2 treatment regimens.

    Didn’t find what you were looking for? 

    Contact us

    Call 01 58 07 34 40*

    *Contact Medical Information. 09h - 18h Monday to Friday.

    Medical Inquiry

    Submit a medical question for Pfizer prescription products.

    Report Adverse Event

    Pfizer Safety 

    To report an adverse event related to the Pfizer-BioNTech COVID-19 vaccines, click the link below:
    www.pfizersafetyreporting.com
    If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please contact Pfizer pharmacovigilance at [email protected].

    Governmental website 

    You may also report adverse events online on the Ministry of Health’s website ‘Portail de signalement des événements sanitaires indésirables’ at https://signalement.social-sante.gouv.fr